The interval between discontinuation of the previous MS treatment and start of prospective treatment with IM IFNb-1a ranged between 13.5 ± 22.3 months (GA) and 33.8 ± 32.2 months (IM IFNb-1a) on average (Table 1). Here, IFNB1 is linked to myeloid sarcoma.